BG Medicine (NASDAQ: BGMD) and Miragen Therapeutics (NASDAQ:MGEN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitabiliy, analyst recommendations, dividends, valuation, earnings and risk.
Analyst Ratings
This is a summary of recent ratings for BG Medicine and Miragen Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BG Medicine | 0 | 0 | 0 | 0 | N/A |
| Miragen Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Miragen Therapeutics has a consensus target price of $10.50, suggesting a potential downside of 26.73%. Given Miragen Therapeutics’ higher possible upside, analysts clearly believe Miragen Therapeutics is more favorable than BG Medicine.
Profitability
This table compares BG Medicine and Miragen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BG Medicine | -311.03% | N/A | -131.82% |
| Miragen Therapeutics | -555.68% | -109.13% | -81.59% |
Institutional and Insider Ownership
16.4% of Miragen Therapeutics shares are held by institutional investors. 44.4% of Miragen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares BG Medicine and Miragen Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| BG Medicine | $1.57 million | 0.34 | -$4.39 million | N/A | N/A |
| Miragen Therapeutics | $3.02 million | 101.58 | -$20.05 million | N/A | N/A |
BG Medicine has higher revenue, but lower earnings than Miragen Therapeutics.
Summary
Miragen Therapeutics beats BG Medicine on 7 of the 10 factors compared between the two stocks.
About BG Medicine
BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners’ automated platforms. The Company’s CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.
About Miragen Therapeutics
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Receive News & Ratings for BG Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
